MedTrace Logo

Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields

NCT03501134 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2021-06-09

No results posted yet for this study

Summary

This purpose of this study is to describe the effect of Tumor Treating Fields (NovoTTF) on quality of life (QOL), including exercise, sleep quality, and mood, in patients with World Health Organization (WHO) Grade IV malignant glioma who have been prescribed and approved to receive Optune™. This is an observational, longitudinal study, meaning that information about QOL will be collected over time while the patient is using the NovoTTF device (for example, Optune™).

Conditions

  • Malignant Glioma

Interventions

DEVICE

NovoTTF

We are studying the effect of Tumor Treating Fields (NovoTTF), for example Optune™, on the quality of life, including exercise, sleep quality, and mood, of patients with malignant glioma who plan to use the NovoTTF device.

Sponsors & Collaborators

Principal Investigators

  • Katherine B Peters, MD, PhD · The Preston Robert Tisch Brain Tumor Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-08
Primary Completion
2021-06-03
Completion
2021-06-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03501134 on ClinicalTrials.gov